Liposome Tech sales and marketing update

The companies delayed sales in December after determining that 14 patients in their 104-patient pivotal trial were not properly evaluated, making it difficult to tell whether they were cured by the original treatment or by Amphocil. The companies voluntarily resubmitted a revised clinical package.

"The U.K. authorities agreed that the resubmitted package didn't effect efficacy or safety issues," Peter Leigh, CFO at LTIZ, told BioCentury. ...